首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas
【2h】

The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas

机译:生长激素释放激素(GHRH)及其受体的剪接变体在人胃肠胰腺癌中的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Splice variants (SVs) of receptors for growth hormone-releasing hormone (GHRH) have been found in primary human prostate cancers and diverse human cancer cell lines. GHRH antagonists inhibit growth of various experimental human cancers, including pancreatic and colorectal, xenografted into nude mice or cultured in vitro, and their antiproliferative action could be mediated in part through SVs of GHRH receptors. In this study we examined the expression of mRNA for GHRH and for SVs of its receptors in tumors of human pancreatic, colorectal, and gastric cancer cell lines grown in nude mice. mRNA for both GHRH and SV1 isoform of GHRH receptors was expressed in tumors of pancreatic (SW1990, PANC-1, MIA PaCa-2, Capan-1, Capan-2, and CFPAC1), colonic (COLO 320DM and HT-29), and gastric (NCI-N87, HS746T, and AGS) cancer cell lines; mRNA for SV2 was also present in Capan-1, Capan-2, CFPAC1, HT-29, and NCI-N87 tumors. In proliferation studies in vitro, the growth of pancreatic, colonic, and gastric cancer cells was stimulated by GHRH(1–29)NH2 and inhibited by GHRH antagonist JV-1–38. The stimulation of some gastroenteropancreatic cancer cells by GHRH was followed by an increase in cAMP production, and GHRH antagonist JV-1–38 competitively inhibited this effect. Our study indicates the presence of an autocrine/paracrine stimulatory loop based on GHRH and SV1 of GHRH receptors in human pancreatic, colorectal, and gastric cancers. The finding of SV1 receptor in human cancers provides an approach to an antitumor therapy based on the blockade of this receptor by specific GHRH antagonists.
机译:生长激素释放激素(GHRH)的受体的剪接变体(SVs)已在原发性人类前列腺癌和多种人类癌细胞系中发现。 GHRH拮抗剂抑制各种实验性人类癌症的生长,包括胰腺癌和结直肠癌,异种移植到裸鼠中或体外培养,它们的抗增殖作用可以部分通过GHRH受体的SV介导。在这项研究中,我们检查了裸鼠中生长的人胰腺癌,结直肠癌和胃癌细胞系肿瘤中GHRH及其受体SV的mRNA表达。 GHRH受体的GHRH和SV1亚型的mRNA在胰腺癌(SW1990,PANC-1,MIA PaCa-2,Capan-1,Capan-2和CFPAC1),结肠癌(COLO 320DM和HT-29)中表达,和胃(NCI-N87,HS746T和AGS)癌细胞系; SV2的mRNA也存在于Capan-1,Capan-2,CFPAC1,HT-29和NCI-N87肿瘤中。在体外增殖研究中,GHRH(1–29)NH2刺激胰腺,结肠和胃癌细胞的生长,GHRH拮抗剂JV-1–38抑制胰腺癌细胞,结肠癌细胞和胃癌细胞的生长。 GHRH刺激某些胃胰腺癌细胞后,cAMP产生增加,而GHRH拮抗剂JV-1–38竞争性地抑制了该作用。我们的研究表明在人胰腺癌,结肠直肠癌和胃癌中存在基于GHRH受体的GHRH和SV1的自分泌/旁分泌刺激环。在人类癌症中发现SV1受体提供了一种基于特定GHRH拮抗剂阻断该受体的抗肿瘤治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号